Eisai Co (ESALF) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Phase 3 LEAP-012 study, officially titled “A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma,” tests if adding Eisai’s lenvatinib and Merck’s pembrolizumab to TACE improves survival in liver cancer patients who cannot have surgery. This update is important for investors because it speaks directly to the future revenue potential of Eisai’s cancer franchise and its role in liver cancer care.
The main treatments in this trial are lenvatinib, sold as Lenvima, and pembrolizumab, sold as Keytruda, used together on top of standard TACE. Lenvatinib is an oral cancer drug that blocks tumor blood vessel growth, while pembrolizumab is an immune therapy that helps the body’s defenses attack cancer cells more effectively.
Participants were randomly assigned to receive either lenvatinib plus pembrolizumab plus TACE or TACE with matching placebos, so that the only difference between groups was the active drugs. The study was double blinded with four-way masking, meaning patients, doctors, study staff, and outcome assessors did not know who was on which treatment, and the main goal was to see if the combination improved how long patients lived without their disease getting worse and overall survival.
The trial began enrollment after first submission on 27 Jan 2020, marking the start of a major push to test this combo in earlier-stage liver cancer. The trial status is now listed as completed, and the record was last updated on 21 Apr 2026, signaling that follow-up is finished and investors should watch for top-line results that could soon shape forecasts for both partners.
For Eisai (ESALF), a positive outcome could support long-term sales of Lenvima beyond current uses and reinforce its strategic tie-up with Merck in oncology. A clear survival benefit could also strengthen the combination’s competitive stance versus other liver cancer regimens and may lift investor sentiment across both Eisai and Merck, while putting pressure on rivals in the hepatocellular carcinoma space.
The LEAP-012 study is completed and recently updated, with full details and future data releases available on the ClinicalTrials.gov portal.
To learn more about ESALF’s potential, visit the Eisai Co drug pipeline page.